Topics

Articles

Originally developed by Ajinomoto for peptide synthesis, the technology has been expanded to include oligonucleotide production

FDA okays first commercial drug manufactured via AJIPHASE technology

Company scaling up manufacturing capacity and anticipates compatibility with its standard distribution channels

J&J and Europe agree on Janssen Covid-19 vaccine candidate, subject to regulatory okay

Trump administration's plan sounds good but faces severe operational obstacles

Drug importation from Canada steps closer to realization

Michael Christel is Group Managing Editor of Pharmaceutical Commerce, Pharmaceutical Executive, and Applied Clinical Trials. He can be reached at mchristel@mjhlifesciences.com.

One expert's take on the key issues at stake

A regulatory view on Covid-19 vaccine outlook

National Academy of Medicine offers a vaccine allocation ‘framework’; will it be followed?

Getting ready for the Covid-19 allocation scramble

Generics trade association is confronting a new, post-pandemic era

AAM has a new CEO, Dan Leonard

Little hope for a flurry of executive orders that revive drug importation and rebate transactions in Medicare

Trump directives to rearrange drug pricing land with a thud

Steady progress is occurring in the global effort to track pharmaceutical distribution, even as new technical and business opportunities appear

Spinning up the pharma traceability wheel

Robert Wood Johnson Foundation-sponsored study assesses the situation

Patient privacy: should industry self-regulate its practices?

Position highlights the move toward more at-home services

Legal and Regulatory